AD Expert Meeting in Penang

Skip to the content

1. What do you think is the percentage of patients with MCI that visit doctors in your country?

<5%
5–10%
10–20%
>20%

2. What are the major challenges in the early detection of AD?
(Please choose 2 most important challenges)

2. What are the major challenges in early detection of AD?

Low awareness among the general public
Low awareness among the non-specialists (PCPs)
Lack of confidence/knowledge for the assessment of AD among specialists
Stigma against the disease
Lack of specialists
No standardised tool/consensus for clinical diagnosis
Others

Please specify :

3. Where in the community do you think you can find patients with early-stage AD?

Clubs/associations for seniors in the local community/city
Nursing home for the elderly
Patient advocacy groups
Annual health check-up for the elderly
Others

Please specify:

4. The importance of confirming amyloid pathology by PET/CSF/blood-based biomarkers (BBBM) is growing recently. Are there any guidelines/recommendation papers that you refer to for the confirmation of amyloid pathology?

NIA-AA guidelines
Appropriate Use Recommendations (US)
Appropriate Use Recommendations (Japan)
CEOi recommendations
Others

Please specify :

5. Do you think it would be necessary to update the guidelines/recommendation papers following the advent of a more biologically-centred definition and diagnosis of Alzheimer’s Disease?

Yes
No

6. Which of the following issues would drive use of BBBM most in your country?

Lack of specialists
Lack of PET/CSF availability
Low diagnosis rate for MCI due to AD/mild AD
Others

7. Given above, at which point in the patient journey would you like to carry out BBBM testing most?
(please see picture below; single choice)

7. Given above, at which point in the patient journey would you like to carry out BBBM testing most?

Screening at health check-up or by PCP (① , ②)
Triage by AD specialist (③）
Confirmatory by AD specialist (④)

Please specify: